Percutaneous Thermal Ablation for Managing Small Renal Metastatic Tumors.

PURPOSE

To retrospectively evaluate the treatment outcomes of thermal ablation for renal metastatic tumors.

MATERIALS AND METHODS

Thirteen consecutive patients with small renal metastatic tumors (≤3 cm), who underwent thermal ablation between 2009 and 2020, were included in this study. Eight patients had extra-renal tumors during renal ablation. The primary tumors were adenoid cystic carcinoma in four patients, lung cancer in three, hemangiopericytoma in three, leiomyosarcoma in two, and thyroid cancer in one. The therapeutic effects, safety, survival rate, prognostic factor, and renal function were evaluated.

RESULTS

We performed 18 ablation sessions (cryoablation, n = 13; radiofrequency ablation, n = 5) on 19 renal metastases with a mean diameter of 1.7 cm, which resulted in a primary technique efficacy rate of 100% without procedure-related deaths or major complications. Renal function significantly declined 6 months after ablation ( = 0.0039). During the mean follow-up period of 31.2 ± 22.4 months (range, 2.7-71.4 months), one patient had local tumor progression at 11.9 months following radiofrequency ablation. The overall survival rates at 1 and 3 years after ablation were 76.9% (95% confidence interval [CI], 54.0%-99.8%) and 59.3% (95% CI, 31.3%-87.3%), respectively. Tumor size ≥ 2 cm ( = 0.02) and metastasis from non-small cell lung cancer ( = 0.001) were significant worse prognostic factors in univariate analysis, and metastasis from non-small cell lung cancer ( = 0.01) was significant in multivariate analysis.

CONCLUSIONS

Percutaneous thermal ablation for small renal metastases is safe and feasible and can control local tumors.